Drugs / Ozagrel
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT01692145 | — | dry eye syndrome | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01890941 | ? → Mar 2014 | dry eye syndrome | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01211951 | — | dry eye syndrome | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01427816 | — | dry eye syndrome | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02503189 | ? → Jan 2017 | dry eye syndrome | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02503176 | ? → May 2017 | dry eye syndrome | Kissei Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT02503163 | ? → Oct 2017 | dry eye syndrome | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00200356 Comparator | Aug 2004 → Oct 2006 | cerebral infarction | Tanabe Pharma Corporation | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ozagrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00200356 ↗ |
| Known as | KCT-0809 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02503176 ↗ |
| Action | Inhibit | “sodium ozagrel (ozagrel), a thromboxane A(2) synthase inhibitor” PMID 19321945 ↗ Mar 20091“Thromboxane-A synthase inhibitor” CHEMBL11662 ↗ |
| Modality | Small molecule | — CHEMBL11662 ↗ |
| Route | Intravenous | “is intravenously administered” NCT00200356 ↗ |
| Target | TBXAS1 | “Thromboxane-A synthase inhibitor” CHEMBL11662 ↗ |